IL83878A
(en)
*
|
1987-09-13 |
1995-07-31 |
Yeda Res & Dev |
Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
|
US6479632B1
(en)
|
1988-09-12 |
2002-11-12 |
Yeda Research And Development Co. Ltd. |
Tumor necrosis factor inhibitory protein and its purification
|
US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
US5811261A
(en)
*
|
1988-09-12 |
1998-09-22 |
Yeda Research And Development Co. Ltd. |
Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US6221675B1
(en)
|
1989-04-21 |
2001-04-24 |
Amgen, Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
US7264944B1
(en)
|
1989-04-21 |
2007-09-04 |
Amgen Inc. |
TNF receptors, TNF binding proteins and DNAs coding for them
|
ATE289350T1
(de)
*
|
1989-04-21 |
2005-03-15 |
Amgen Inc |
Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
|
CA2017025C
(en)
*
|
1989-05-18 |
2008-07-22 |
David Wallach |
Tumor necrosis factor binding protein ii, its purification and antibodies thereto
|
US6232446B1
(en)
*
|
1989-05-18 |
2001-05-15 |
Yeda Research And Development Co. Ltd. |
TNF ligands
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
US6143866A
(en)
*
|
1989-07-18 |
2000-11-07 |
Amgen, Inc. |
Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
|
CA2064915C
(en)
*
|
1989-08-07 |
2001-05-29 |
Deborah A. Rathjen |
Tumour necrosis factor binding ligands
|
US20030225254A1
(en)
*
|
1989-08-07 |
2003-12-04 |
Rathjen Deborah Ann |
Tumour necrosis factor binding ligands
|
US5959087A
(en)
*
|
1989-08-07 |
1999-09-28 |
Peptide Technology, Ltd. |
Tumour necrosis factor binding ligands
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
US5395760A
(en)
*
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
US5945397A
(en)
*
|
1989-09-05 |
1999-08-31 |
Immunex Corporation |
Purified p75 (type II) tumor necrosis factor receptor polypeptides
|
NZ235148A
(en)
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
EP0417563B1
(de)
|
1989-09-12 |
2000-07-05 |
F. Hoffmann-La Roche Ag |
TNF-bindende Proteine
|
US6552170B1
(en)
*
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US7253264B1
(en)
|
1990-06-28 |
2007-08-07 |
Sanofi-Arentideutschland GmbH |
Immunoglobulin fusion proteins, their production and use
|
ATE309376T1
(de)
*
|
1990-06-28 |
2005-11-15 |
Hoechst Ag |
Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
|
US20030064480A1
(en)
*
|
1990-06-28 |
2003-04-03 |
Leander Lauffer |
Fusion proteins with immunoglobulin portions, the preparation and use thereof
|
EP0533006A1
(en)
*
|
1991-09-18 |
1993-03-24 |
F.Hoffmann-La Roche & Co. Aktiengesellschaft |
Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
|
WO1993019777A1
(en)
*
|
1992-03-30 |
1993-10-14 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
IL104355A
(en)
*
|
1993-01-10 |
2006-08-20 |
Yeda Res & Dev |
Tnf receptor promoter
|
US5795975A
(en)
*
|
1993-01-10 |
1998-08-18 |
Yeda Research And Development Co. Ltd. |
TNF receptor promoter
|
EP1004312A1
(en)
*
|
1993-07-30 |
2000-05-31 |
Kennedy Institute Of Rheumatology |
Method for treating multiple sclerosis
|
CA2139385C
(en)
*
|
1994-02-04 |
2001-12-25 |
Gottfried Alber |
Products containing g-csf and tnf binding protein
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
AU747029B2
(en)
*
|
1994-05-11 |
2002-05-09 |
Yeda Research And Development Co. Ltd. |
Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
|
IL111125A0
(en)
*
|
1994-05-11 |
1994-12-29 |
Yeda Res & Dev |
Soluble oligomeric tnf/ngf super family ligand receptors and their use
|
US6579697B1
(en)
*
|
1995-05-11 |
2003-06-17 |
Yeda Research And Development Co. Ltd. |
Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
|
US5708142A
(en)
*
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
US5741667A
(en)
*
|
1994-05-27 |
1998-04-21 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
CA2195665A1
(en)
*
|
1994-07-22 |
1996-02-08 |
Robert Frederick Geoffrey Booth |
Pharmaceutical compositions comprising a chimaeric tnf binding protein
|
US7070783B1
(en)
*
|
1995-05-09 |
2006-07-04 |
The Mathilda And Terence Kennedy Institute Of Rheumatology |
Small molecular weight TNF receptor multimeric molecule
|
US5705364A
(en)
|
1995-06-06 |
1998-01-06 |
Genentech, Inc. |
Mammalian cell culture process
|
ZA966663B
(en)
*
|
1995-08-17 |
1998-02-06 |
Genentech Inc |
Traf Inhibitors.
|
US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US6030945A
(en)
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
US6469144B1
(en)
|
1996-04-01 |
2002-10-22 |
Genentech, Inc. |
Apo-2LI and Apo-3 polypeptides
|
CA2253557A1
(en)
*
|
1996-05-08 |
1997-11-13 |
Louis Martin Renzetti |
Treatment of asthma with tnfr-ig
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
EP2002846B1
(en)
|
1996-12-06 |
2017-01-25 |
Amgen Inc. |
Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
|
ATE247974T1
(de)
|
1996-12-06 |
2003-09-15 |
Amgen Inc |
Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
|
WO1998058062A1
(en)
|
1997-06-18 |
1998-12-23 |
Genentech, Inc. |
Apo-2DcR
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
PT1015587E
(pt)
|
1997-09-18 |
2008-07-31 |
Genentech Inc |
Polipéptido dcr3, um homólogo de tnfr
|
WO1999019490A1
(en)
|
1997-10-10 |
1999-04-22 |
Genentech, Inc. |
Apo-3 ligand
|
AU2325199A
(en)
|
1998-01-15 |
1999-08-02 |
Genentech Inc. |
Apo-2 ligand
|
EP2050762A3
(en)
|
1998-03-10 |
2009-07-08 |
Genentech, Inc. |
Human cornichon-like protein and nucleic acids encoding it
|
US8197430B1
(en)
*
|
1998-05-22 |
2012-06-12 |
Biopheresis Technologies, Inc. |
Method and system to remove cytokine inhibitor in patients
|
US6620382B1
(en)
*
|
1998-05-22 |
2003-09-16 |
Biopheresis Technologies, Llc. |
Method and compositions for treatment of cancers
|
WO2000021981A2
(de)
*
|
1998-10-09 |
2000-04-20 |
Bioserv Ag |
TNFα BINDENDE PEPTIDE UND IHRE ANWENDUNG FÜR DIE DETEKTION, INAKTIVIERUNG UND/ODER ENTFERNUNG VON TNFα AUS BIOLOGISCHEN FLÜSSIGKEITEN
|
MY126795A
(en)
*
|
1998-10-23 |
2006-10-31 |
Amgen K A Inc |
Dimeric thrombopoietic peptide mimetics binding to mp1 receptor and having thrombopoietic activity.
|
US6660843B1
(en)
*
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
WO2000032826A1
(en)
*
|
1998-11-30 |
2000-06-08 |
Drexel University |
Methods and kits for identifying individuals at risk of developing osteoporosis
|
JP4716578B2
(ja)
|
1999-04-12 |
2011-07-06 |
ジェネンテック, インコーポレイテッド |
腫瘍壊死因子相同体及びそれをコードする核酸
|
US20040220103A1
(en)
|
1999-04-19 |
2004-11-04 |
Immunex Corporation |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
DE60043322D1
(de)
|
1999-06-15 |
2009-12-24 |
Genentech Inc |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
|
AU6338200A
(en)
|
1999-06-28 |
2001-01-31 |
Genentech Inc. |
Methods for making apo-2 ligand using divalent metal ions
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US6808902B1
(en)
*
|
1999-11-12 |
2004-10-26 |
Amgen Inc. |
Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
|
BR0108193A
(pt)
*
|
2000-02-10 |
2003-02-25 |
Wyeth Corp |
Processo para tratamento ou inibição de dano celular ou morte celular
|
EP1255558B1
(en)
|
2000-02-16 |
2006-06-14 |
Genentech, Inc. |
Anti-april antibodies and hybridoma cells
|
JP2003525612A
(ja)
|
2000-03-02 |
2003-09-02 |
ゼンコー |
TNF−α関連障害の処置のための変種TNF−αタンパク質の設計および発見
|
BR0001078A
(pt)
*
|
2000-04-06 |
2003-05-13 |
Maria Amalia Rotolo De Moraes |
Método e aparelho de estìmulo positivo mental
|
IL151853A0
(en)
|
2000-04-11 |
2003-04-10 |
Genentech Inc |
Multivalent antibodies and uses therefor
|
PT1303293E
(pt)
|
2000-07-27 |
2009-03-11 |
Genentech Inc |
Administração sequencial de cpt-11 e polipéptido apo-2l
|
MXPA03007878A
(es)
*
|
2001-03-02 |
2004-07-08 |
Medimmune Inc |
Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina.
|
WO2003002187A2
(en)
*
|
2001-06-26 |
2003-01-09 |
Photomed Technologies, Inc. |
Multiple wavelength illuminator
|
DE122010000047I1
(de)
|
2001-06-26 |
2011-05-05 |
Amgen Fremont Inc |
Antikörper gegen opgl
|
US20050271663A1
(en)
*
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
US20060073141A1
(en)
*
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
JP4509570B2
(ja)
|
2001-07-03 |
2010-07-21 |
ジェネンテック, インコーポレイテッド |
ヒトdr4抗体及びその使用法
|
IL160127A0
(en)
*
|
2001-08-03 |
2004-06-20 |
Genentech Inc |
Tacis and br3 polypeptides and uses thereof
|
IL161051A0
(en)
|
2001-10-02 |
2004-08-31 |
Genentech Inc |
Apo-2 ligand variants and uses thereof
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7205275B2
(en)
|
2001-10-11 |
2007-04-17 |
Amgen Inc. |
Methods of treatment using specific binding agents of human angiopoietin-2
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7842668B1
(en)
|
2001-11-13 |
2010-11-30 |
Genentech, Inc. |
Apo-2 ligand/trail formulations
|
DE60237841D1
(de)
|
2001-11-13 |
2010-11-11 |
Genentech Inc |
Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
|
US7741285B2
(en)
*
|
2001-11-13 |
2010-06-22 |
Genentech, Inc. |
APO-2 ligand/trail formulations
|
ATE425989T1
(de)
*
|
2001-12-21 |
2009-04-15 |
Immunex Corp |
Proteinreinigungsverfahren
|
WO2003072060A2
(en)
*
|
2002-02-27 |
2003-09-04 |
Immunex Corporation |
Polypeptide formulation
|
MXPA04009381A
(es)
|
2002-03-27 |
2005-01-25 |
Immunex Corp |
Metodos para incrementar la produccion de polipeptidos.
|
CA2481747A1
(en)
|
2002-04-12 |
2003-10-23 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
EP1556076A4
(en)
|
2002-06-24 |
2009-07-08 |
Genentech Inc |
APO-2 LIGAND / TRAIL VARIANTS AND ITS USES
|
US20080008713A1
(en)
*
|
2002-06-28 |
2008-01-10 |
Domantis Limited |
Single domain antibodies against tnfr1 and methods of use therefor
|
US9028822B2
(en)
|
2002-06-28 |
2015-05-12 |
Domantis Limited |
Antagonists against TNFR1 and methods of use therefor
|
US20060002935A1
(en)
*
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
AU2003256836A1
(en)
*
|
2002-07-25 |
2004-02-16 |
Genentech, Inc. |
Taci antibodies and uses thereof
|
MXPA05007019A
(es)
|
2002-12-30 |
2005-08-18 |
Amgen Inc |
Terapia de combinacion con factores co-estimuladores.
|
US7101978B2
(en)
*
|
2003-01-08 |
2006-09-05 |
Applied Molecular Evolution |
TNF-α binding molecules
|
KR20120035234A
(ko)
|
2003-04-11 |
2012-04-13 |
메디뮨 엘엘씨 |
재조합 il?9 항체 및 그의 용도
|
US20050037947A1
(en)
*
|
2003-05-06 |
2005-02-17 |
Bitonti Alan J. |
Inhibition of drug binding to serum albumin
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
SI1624891T2
(sl)
*
|
2003-05-06 |
2013-09-30 |
Biogen Idec Hemophilia Inc. |
Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
CA2526402A1
(en)
*
|
2003-06-05 |
2005-01-20 |
Genentech, Inc. |
Blys antagonists and uses thereof
|
WO2005004795A2
(en)
*
|
2003-06-09 |
2005-01-20 |
University Of Cincinnati |
Compositions and methods for targeted drug delivery
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
US7435799B2
(en)
*
|
2004-01-08 |
2008-10-14 |
Applied Molecular Evolution |
TNF-α binding molecules
|
CA2553187A1
(en)
*
|
2004-01-28 |
2005-08-11 |
Syntonix Pharmaceuticals, Inc. |
Heterodimeric follicle stimulating hormone-fc (fsh-fc) fusion proteins for the treatment of infertility
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
SI1949915T1
(sl)
*
|
2004-04-30 |
2012-12-31 |
Biopheresis Technologies, Inc. |
Postopek in sistem za odstranitev topnih TNFR1, TNFR2 in IL2R pri pacientih
|
MX2007000216A
(es)
*
|
2004-07-08 |
2007-03-15 |
Amgen Inc |
Peptidos terapeuticos.
|
CN101035912A
(zh)
|
2004-08-06 |
2007-09-12 |
健泰科生物技术公司 |
使用生物标志的测定法和方法
|
EP1774037B1
(en)
|
2004-08-06 |
2011-05-11 |
Genentech, Inc. |
Assays and methods using biomarkers
|
TWI384069B
(zh)
|
2004-08-27 |
2013-02-01 |
Pfizer Ireland Pharmaceuticals |
多胜肽之製法
|
TWI374935B
(en)
|
2004-08-27 |
2012-10-21 |
Pfizer Ireland Pharmaceuticals |
Production of α-abeta
|
TWI364458B
(en)
|
2004-08-27 |
2012-05-21 |
Wyeth Res Ireland Ltd |
Production of tnfr-lg
|
EA011879B1
(ru)
|
2004-09-24 |
2009-06-30 |
Эмджин Инк. |
МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
|
US20060121042A1
(en)
|
2004-10-27 |
2006-06-08 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
DK1838736T3
(da)
|
2005-01-05 |
2013-06-03 |
Biogen Idec Inc |
Cripto-bindende molekyler
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
WO2006138181A2
(en)
|
2005-06-14 |
2006-12-28 |
Amgen Inc. |
Self-buffering protein formulations
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
ZA200800974B
(en)
|
2005-08-16 |
2009-11-25 |
Genentech Inc |
Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
|
US8741260B2
(en)
*
|
2005-10-07 |
2014-06-03 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of GDNF to the CNS
|
PE20070796A1
(es)
*
|
2005-10-24 |
2007-08-15 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
US7785834B2
(en)
*
|
2005-11-10 |
2010-08-31 |
Ercole Biotech, Inc. |
Soluble TNF receptors and their use in treatment of disease
|
EP2535413A3
(en)
*
|
2005-11-10 |
2016-04-13 |
Roche Innovation Center Copenhagen A/S |
Splice switching oligomers for the TNF superfamily receptors and their use in treatment of disease
|
US7820165B2
(en)
|
2005-11-21 |
2010-10-26 |
Merck Serono, S.A. |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
US9726673B2
(en)
|
2005-11-23 |
2017-08-08 |
Genentech, Inc. |
Methods and compositions related to B cell assays
|
JO3324B1
(ar)
|
2006-04-21 |
2019-03-13 |
Amgen Inc |
مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
|
WO2008008373A2
(en)
|
2006-07-11 |
2008-01-17 |
Arubor Corp |
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
|
PL2041270T3
(pl)
|
2006-07-13 |
2014-04-30 |
Wyeth Llc |
Wytwarzanie glikoprotein
|
EP3669878A1
(en)
|
2006-08-10 |
2020-06-24 |
Roy C. Levitt |
Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
|
US8497246B2
(en)
|
2006-08-18 |
2013-07-30 |
Armagen Technologies, Inc. |
Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
CA2665423A1
(en)
|
2006-10-12 |
2008-04-17 |
Wyeth |
Methods and compositions with reduced opalescence
|
US20090264353A1
(en)
*
|
2007-10-19 |
2009-10-22 |
Santaris Pharma A/S |
Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
|
ES2541546T3
(es)
|
2006-11-03 |
2015-07-21 |
Wyeth Llc |
Sustancias que inhiben la glucólisis en cultivo celular
|
RU2009128039A
(ru)
*
|
2006-12-22 |
2011-01-27 |
Дженентек, Инк. (Us) |
Антагонисты dr6 и способы их применения в лечении неврологических нарушений
|
CN101679941A
(zh)
|
2007-03-02 |
2010-03-24 |
惠氏公司 |
在细胞培养物中使用铜和谷氨酸盐生产多肽
|
TW200902708A
(en)
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
EP2737907A3
(en)
|
2007-05-07 |
2014-11-05 |
MedImmune, LLC |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
NZ580530A
(en)
*
|
2007-06-06 |
2012-04-27 |
Domantis Ltd |
Anti vegf polypeptides, antibody variable domains and antagonists
|
EP2182980A4
(en)
|
2007-07-27 |
2012-04-18 |
Armagen Technologies Inc |
METHOD AND COMPOSITIONS FOR INCREASED ALPHA IDURONIDASE ACTIVITY IN THE CNS
|
ES2517603T3
(es)
|
2008-04-07 |
2014-11-03 |
Bayer Healthcare, Llc |
Procedimientos de producción recombinante de glucoproteínas
|
KR20110028504A
(ko)
*
|
2008-06-12 |
2011-03-18 |
제넨테크, 인크. |
신경변성을 억제하는 화합물의 스크리닝 방법
|
CA2743469C
(en)
|
2008-11-12 |
2019-01-15 |
Medimmune, Llc |
Antibody formulation
|
EP2376120A2
(en)
|
2008-11-25 |
2011-10-19 |
Biogen Idec MA Inc. |
Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
|
EP2408474B1
(en)
*
|
2009-03-18 |
2019-06-26 |
Armagen, Inc. |
Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
|
RU2011142230A
(ru)
|
2009-04-20 |
2013-05-27 |
Пфайзер Инк. |
Контроль гликозилирования белка и композиции и способы, касающиеся этого
|
NZ714757A
(en)
|
2009-08-14 |
2018-07-27 |
Us Gov Health & Human Services |
Use of il-15 to increase thymic output and to treat lymphopenia
|
HUE044865T2
(hu)
|
2009-10-09 |
2019-11-28 |
Armagen Inc |
Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
|
CN102686606A
(zh)
*
|
2009-10-09 |
2012-09-19 |
阿纳福公司 |
结合il-23r的多肽
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
MX2012005464A
(es)
*
|
2009-11-12 |
2012-06-08 |
Genentech Inc |
Un metodo para promover la densidad de espinas dendriticas.
|
WO2011068993A1
(en)
*
|
2009-12-02 |
2011-06-09 |
Acceleron Pharma Inc. |
Compositions and methods for increasing serum half-life of fc fusion proteins.
|
PT2523688T
(pt)
|
2010-01-15 |
2018-01-05 |
Kirin Amgen Inc |
Formulação de anticorpo e regimes terapêuticos
|
EP3552619A1
(en)
|
2010-07-09 |
2019-10-16 |
Bioverativ Therapeutics Inc. |
Factor ix polypeptides and methods of use thereof
|
EP2591099B1
(en)
|
2010-07-09 |
2020-11-18 |
Bioverativ Therapeutics Inc. |
Chimeric clotting factors
|
EP3508573A1
(en)
|
2010-07-09 |
2019-07-10 |
Bioverativ Therapeutics Inc. |
Systems for factor viii processing and methods thereof
|
CN103080300B
(zh)
|
2010-08-05 |
2015-11-25 |
安姆根有限公司 |
增加细胞培养物的产率和活力的二肽
|
EP2606119A1
(en)
|
2010-08-20 |
2013-06-26 |
Wyeth LLC |
Cell culture of growth factor-free adapted cells
|
JP6004494B2
(ja)
*
|
2010-10-30 |
2016-10-12 |
オックスフォード ユニバーシティ イノベーション リミテッド |
デュピュイトラン病の治療
|
US9133493B2
(en)
|
2011-04-21 |
2015-09-15 |
Amgen Inc. |
Method for culturing mammalian cells to improve recombinant protein production
|
US8883982B2
(en)
|
2011-06-08 |
2014-11-11 |
Acceleron Pharma, Inc. |
Compositions and methods for increasing serum half-life
|
AU2012279230B2
(en)
|
2011-07-01 |
2016-08-18 |
Amgen Inc. |
Mammalian cell culture
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
CN103930134B
(zh)
|
2011-07-18 |
2016-12-21 |
阿茨生物股份有限公司 |
长效促黄体激素(lh)化合物
|
US20140234330A1
(en)
|
2011-07-22 |
2014-08-21 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
BR112014004591A2
(pt)
|
2011-09-02 |
2017-03-28 |
Amgen Inc |
produto farmacêutico de análise da exposição à luz de um produto farmacêutico
|
ES2942483T3
(es)
|
2011-10-05 |
2023-06-01 |
Oned Mat Inc |
Materiales activos de nanoestructuras de silicio para baterías de iones de litio y procesos, composiciones, componentes y dispositivos relacionados con los mismos
|
WO2013057628A1
(en)
|
2011-10-21 |
2013-04-25 |
Pfizer Inc. |
Addition of iron to improve cell culture
|
CN105688188A
(zh)
|
2011-11-18 |
2016-06-22 |
瑞泽恩制药公司 |
聚合物蛋白微粒
|
KR20140100543A
(ko)
|
2011-11-29 |
2014-08-14 |
뉴로페이지 파마슈티컬즈, 인크. |
박테리오파아지 유전자 3 단백질 조성물 및 아밀로이드 결합제로서의 용도
|
EP2785378B1
(en)
|
2011-12-02 |
2020-05-13 |
Armagen, Inc. |
Methods and compositions for increasing arylsulfatase a activity in the cns
|
AR089231A1
(es)
|
2011-12-15 |
2014-08-06 |
Amgen Inc |
Metodo de floculacion
|
KR102104686B1
(ko)
|
2012-01-10 |
2020-04-24 |
바이오젠 엠에이 인코포레이티드 |
뇌혈관 장벽을 통한 치료학적 분자의 수송 개선법
|
EP2846822A2
(en)
|
2012-05-11 |
2015-03-18 |
Prorec Bio AB |
Method for diagnosis and treatment of prolactin associated disorders
|
WO2014043103A1
(en)
|
2012-09-11 |
2014-03-20 |
Coherus Biosciences, Inc. |
Correctly folded etanercept in high purity and excellent yield
|
WO2014055515A1
(en)
|
2012-10-02 |
2014-04-10 |
Neurophage Pharmaceuticals, Inc. |
Use of p3 of bacteriophage fusion proteins as amyloid binding agents
|
CN103509121B
(zh)
|
2012-11-22 |
2015-01-28 |
苏州康宁杰瑞生物科技有限公司 |
一种fsh融合蛋白及其制备方法和用途
|
US20140199728A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
CN104955480A
(zh)
|
2013-01-25 |
2015-09-30 |
西蒙有限公司 |
用于选择性减少循环的生物活性可溶性tnf的组合物以及用于治疗tnf介导的疾病的方法
|
TWI625390B
(zh)
|
2013-03-14 |
2018-06-01 |
安美基公司 |
用於增加重組蛋白質之甘露糖含量之方法
|
HUE038565T2
(hu)
|
2013-03-14 |
2018-10-29 |
Amgen Inc |
Kiszivárgott affinitás tisztító ligandumok eltávolítása
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
SG11201505926VA
(en)
|
2013-03-15 |
2015-09-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
EA030389B1
(ru)
|
2013-05-28 |
2018-07-31 |
Проклара Байосайенсиз, Инк. |
ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ ИЗМЕНЕННУЮ АМИНОКИСЛОТНУЮ ПОСЛЕДОВАТЕЛЬНОСТЬ g3p БАКТЕРИОФАГА С ПОНИЖЕННОЙ ИММУНОГЕННОСТЬЮ
|
US9481901B2
(en)
|
2013-05-30 |
2016-11-01 |
Amgen Inc. |
Methods for increasing mannose content of recombinant proteins
|
CA2929077A1
(en)
|
2013-10-31 |
2015-05-07 |
Amgen Inc. |
Use of monensin to regulate glycosylation of recombinant proteins
|
US10513723B2
(en)
|
2014-01-13 |
2019-12-24 |
Amgen Inc. |
Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
EA202190244A3
(ru)
|
2014-01-29 |
2021-08-31 |
Эмджен Инк. |
Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
|
PL3099713T3
(pl)
|
2014-02-02 |
2020-06-29 |
Medimmune Limited |
Białko chimeryczne złożone z domeny antagonisty ngf i domeny antagonisty tnfa
|
JP6596014B2
(ja)
|
2014-03-31 |
2019-10-23 |
アムジェン ケー・エー,インコーポレイテッド |
爪および頭皮乾癬の治療方法
|
ES2709994T3
(es)
|
2014-06-04 |
2019-04-22 |
Amgen Inc |
Métodos de recolección en cultivos de células de mamífero
|
MX2017006463A
(es)
|
2014-11-19 |
2018-04-20 |
Amgen Inc |
Cuantificacion de porcion de glicano en glicoproteinas recombinantes.
|
PT3227454T
(pt)
|
2014-12-01 |
2020-04-06 |
Amgen Inc |
Processo para a manipulação do nível do teor de glicano de uma glicoproteína
|
TW201632542A
(zh)
|
2014-12-03 |
2016-09-16 |
神經噬菌體製藥股份有限公司 |
包含缺乏醣基化信號之修飾噬菌體g3p胺基酸序列的多肽
|
CA2971186A1
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of California |
Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
|
ES2824151T3
(es)
|
2014-12-19 |
2021-05-11 |
Alkermes Inc |
Proteínas de fusión Fc monocatenarias
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
WO2016127000A1
(en)
|
2015-02-04 |
2016-08-11 |
Bristol-Myers Squibb Company |
Methods of selecting therapeutic molecules
|
WO2016149139A1
(en)
|
2015-03-13 |
2016-09-22 |
Samsung Bioepis Co., Ltd. |
Anti-tnf-alpha polypeptide composition and use thereof
|
TW202330904A
(zh)
|
2015-08-04 |
2023-08-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
WO2017106716A1
(en)
|
2015-12-16 |
2017-06-22 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods of manufacturing protein microparticles
|
CA3026393C
(en)
|
2016-06-22 |
2023-03-14 |
Alkermes, Inc. |
Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
|
HUP1600456A2
(en)
|
2016-07-19 |
2018-01-29 |
Richter Gedeon Nyrt |
Novel cell-based tnf-alpha binding assay
|
CN109963590B
(zh)
|
2016-09-02 |
2024-03-15 |
加利福尼亚大学董事会 |
涉及白介素-6受体α结合单链可变片段的方法和组合物
|
WO2018075818A1
(en)
|
2016-10-21 |
2018-04-26 |
Amgen Inc. |
Pharmaceutical formulations and methods of making the same
|
BR112019011860A2
(pt)
|
2016-12-09 |
2019-11-12 |
Akston Biosciences Corp |
proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune
|
WO2019010191A1
(en)
|
2017-07-06 |
2019-01-10 |
Regeneron Pharmaceuticals, Inc. |
CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN
|
US20210031012A1
(en)
|
2018-01-26 |
2021-02-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
US20230312700A1
(en)
|
2018-06-20 |
2023-10-05 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
EP3810094A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
WO2019246455A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
WO2019246271A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
US11952399B2
(en)
|
2018-12-18 |
2024-04-09 |
Amgen Inc. |
Methods for purifying proteins
|
IL294765B2
(en)
|
2020-01-21 |
2023-12-01 |
Regeneron Pharma |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
JP2024503239A
(ja)
|
2020-12-22 |
2024-01-25 |
アムジェン インコーポレイテッド |
細胞培養法
|
TW202340245A
(zh)
|
2021-07-27 |
2023-10-16 |
瑞典商阿斯特捷利康公司 |
狼瘡之治療
|
TW202323817A
(zh)
|
2021-10-07 |
2023-06-16 |
美商再生元醫藥公司 |
Ph建模及控制之系統及方法
|
US20230110811A1
(en)
|
2021-10-07 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
pH METER CALIBRATION AND CORRECTION
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|